MedTrace Logo

Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites

NCT02496286 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-07-12

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of intraperitoneal administration of Bevacizumab to prevent the recurrence of malignant ascites. Ten patients will receive intraperitoneal Bevacizumab 200 mg in 250 ml of normal saline for infusion every two weeks for up to six weeks, or a maximum of three treatments.

Conditions

  • Malignant Ascites

Interventions

DRUG

Intraperitoneal Bevacizumab

Bevacizumab 200mg diluted in 250 ml of normal saline

Sponsors & Collaborators

  • Eastern Regional Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02496286 on ClinicalTrials.gov